Micro- and nanoplastics and fecal microbiota transplantation: a conceptual framework linking gut dysbiosis and intestinal barrier dysfunction
International Journal of Pharmaceutics: X · 2026-12 · 12 · 100699
DOI: 10.1016/j.ijpx.2026.100699 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Pharmaceutics: X, 2026-12. Verfasst von Qiuyue Tu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China. Die Arbeit nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Fecal microbiota transplantation (FMT) is increasingly recognized as a promising therapeutic option for microbiota-related disorders. Its efficacy may be affected by factors related to both donor microbiota and the recipient's intestinal barrier. Micro- and nanoplastics (MNPs), emerging environmental contaminants, have been recognized for their detrimental impacts on intestinal health. Existing studies have shown that MNPs can induce gut dysbiosis, impair intestinal barrier, and alter mucosal immune responses. These findings raise the possibility that MNPs may influence biological processes relevant to FMT, including donor microbiota characteristics and the recipient intestinal microenvironment. However, evidence of MNPs-induced intestinal toxicity does not establish impaired donor microbial engraftment or reduced therapeutic FMT efficacy, and the proposed relationship remains untested. Furthermore, although MNPs release from medical materials has been reported, whether FMT procedures contribute to measurable MNPs exposure remains unknown. This review summarizes current evidence on MNPs-associated intestinal health and proposes a potential mechanistic framework linking MNPs exposure to FMT outcomes, through alterations in gut microbiota, and intestinal barrier. Future studies are needed to validate this proposed framework by directly investigating the effects of MNPs exposure on donor microbial engraftment, microbial functional recovery, and clinical outcomes following FMT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.
- Department of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
- Shenzhen Clinical Research Center for Digestive Disease, Shenzhen, Guangdong, China.
- Microbiota I-Center, Hong Kong SAR, China.
- Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, China.
- MOE Key Laboratory of Pollution Processes and Environmental Criteria, College of Environmental Science and Engineering, Nankai University, Tianjin, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Tu, Q., Li, H., Li, J., Feng, Z., Wei, X., Zhang, H., Yi, Q., Lin, H., Zhang, Y., Li, Y., Li, X., Wang, Y., Chen, Y., Su, Q., Wang, L., & Cao, X. (2026). Micro- and nanoplastics and fecal microbiota transplantation: a conceptual framework linking gut dysbiosis and intestinal barrier dysfunction. International Journal of Pharmaceutics: X, 12, 100699. https://doi.org/10.1016/j.ijpx.2026.100699
Vancouver
Tu Q, Li H, Li J, Feng Z, Wei X, Zhang H, et al. Micro- and nanoplastics and fecal microbiota transplantation: a conceptual framework linking gut dysbiosis and intestinal barrier dysfunction. International Journal of Pharmaceutics: X. 2026;12:100699. doi:10.1016/j.ijpx.2026.100699
BibTeX
@article{Tu2026,
author = {Tu, Qiuyue and Li, Huizhen and Li, Jiaxin and Feng, Zelin and Wei, Xinyue and Zhang, Hetong and Yi, Qinghua and Lin, Haojia and Zhang, Yanru and Li, Yueting and Li, Xiaoqin and Wang, Yu and Chen, Ye and Su, Qi and Wang, Lei and Cao, Xiaocang},
title = {Micro- and nanoplastics and fecal microbiota transplantation: a conceptual framework linking gut dysbiosis and intestinal barrier dysfunction},
journal = {International Journal of Pharmaceutics: X},
year = {2026},
volume = {12},
pages = {100699},
doi = {10.1016/j.ijpx.2026.100699}
}
EUVIMED